Clinical Trial Update: PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Velcade (bortezomib) to high-dose dexamethasone in relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED